Investment
Features
FeesSafety
Academy
More
Pluang+

Compare American Homes 4 Rent Class A (AMH) vs BioNTech SE - ADR (BNTX) Price & Performance

American Homes 4 Rent Class A
BioNTech SE - ADR

Price performance

Price movement over the last 24 hours

Key statistics

American Homes 4 Rent Class A vs BioNTech SE - ADR — how do they compare? American Homes 4 Rent Class A trades at $33.27 (market cap $11.97B), while BioNTech SE - ADR trades at $90.84 (market cap $23.14B). The key difference: BioNTech SE - ADR is the larger of the two by market cap, and American Homes 4 Rent Class A pays a 3.97% dividend while BioNTech SE - ADR pays none. Which is the better fit depends on your goals.

AMHBNTX
Market Cap
$11.97B$23.14B
Sector
Real EstateHealth
52-Week High
$36.74$119.34
52-Week Low
$27.38$83.89
Enterprise Value
$17.05B$6.81B
Dividend Yield
3.97%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

American Homes 4 Rent Class A

AMH (American Homes 4 Rent) trades at $33.27, up 1.0% with a bullish technical signal and strong earnings momentum after beating estimates for three consecutive quarters. The company maintains robust fundamentals with 24.48% net income margin and $1.85B revenue in 2025, supported by 95% occupancy rates in the single-family rental market. Recent dividend declaration of $0.33 per share and positive analyst sentiment with 58% buy ratings reinforce strength.

Outlook remains positive given consistent operational performance and strategic focus on Sunbelt and Midwest markets. Key risks include high debt levels at $5.01B and sensitivity to interest rate changes. With consensus price target of $35.68 offering 7.2% upside, the stock presents a compelling opportunity for income and growth investors despite macroeconomic headwinds.

BioNTech SE - ADR

BNTX trades at $91.49, down 1.6% on the day, with a mixed technical picture showing a bullish overall signal but bearish moving averages. The company reported a net loss of $1.14 billion for 2025, with revenue of $2.87 billion, and is undergoing a strategic shift toward oncology, including a $1 billion share buyback and manufacturing site closures affecting 1,860 jobs. Analyst consensus is strongly bullish with a $129.67 price target.

The outlook hinges on BioNTech's transition from COVID-19 vaccine dependency to oncology pipeline success. Opportunities include a strong cash position of $16.78 billion and promising clinical data, but risks involve execution challenges, sustained losses, and competitive pressures in the biotech sector.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About American Homes 4 Rent Class A

American Homes 4 Rent is a real estate investment trust primarily focused on acquiring, operating, and leasing single-family homes as rental properties throughout the United States. The company's real estate portfolio is largely comprised of single-family properties in urban markets in the Southern and Midwestern regions of the U.S. American Homes 4 Rent's land holdings also represent a sizable percentage of its total assets in terms of value. The company derives the vast majority of its income in the form of rental revenue from single-family properties through short-term or annual leases. The firm's largest geographical markets include Dallas, Texas

Read more on AMH

About BioNTech SE - ADR

BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.

Read more on BNTX